3-HO-PCP (3-hydroxyphencyclidine) is a synthetic dissociative of the arylcyclohexylamine class, a hydroxylated analog of phencyclidine (PCP). It is pharmacologically distinguished from most other dissociatives by its dual mechanism: potent NMDA receptor antagonism combined with significant mu-opioid receptor agonist activity. This dual pharmacology makes 3-HO-PCP substantially more dangerous than ketamine or PCP analogs that lack opioid activity, and places it in a risk category comparable to opioid-dissociative polydrug combinations.
Community experience with 3-HO-PCP is substantial relative to its obscurity — the Reddit community contains numerous discussion threads covering its unusual warmth and euphoria (attributable to opioid activity), its potential for compulsive use, its paradoxical combination of dissociative and opiate-like qualities, and several cautionary accounts including one describing a 50 mg experience as psychologically extreme ("A Clockwork Tan"). Multiple discussions address the risk of opioid withdrawal reactivation in individuals with prior opioid use disorder — a clinically critical concern. Community members consistently compare it favorably to other dissociatives for euphoria while acknowledging it is among the most physiologically hazardous in the class.
The opioid activity gives 3-HO-PCP overdose characteristics distinct from pure dissociatives: respiratory depression can occur at doses that produce intense dissociation, and the combination with other opioids or CNS depressants can be fatal. Naloxone can partially reverse 3-HO-PCP effects, but incomplete reversal of NMDA antagonism means it may not fully resolve an overdose.
Safety at a Glance
High Risk- Naloxone Is Essential
- The risk of respiratory depression makes solo use of 3-HO-PCP genuinely life-threatening. A sober companion who under...
- Toxicity: Respiratory Depression — Highest Priority Risk 3-HO-PCP's opioid activity creates clinically significant respiratory ...
- Dangerous with: Acetylfentanyl, Buprenorphine, Codeine, Desomorphine (+15 more)
- Overdose risk: Overdose on 3-HO-PCP can range from unpleasant to life-threatening depending on the dose, route, ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4 hrs – 6 hrsHow It Feels
It arrives as warmth — a deep, almost narcotic heat that pools in the center of the body and radiates outward with each heartbeat. Within twenty minutes the familiar architecture of the self begins to loosen. The edges of your body grow indistinct, as though your skin has become a suggestion rather than a boundary. There is something immediately seductive about this compound: it feels good in a way that is simultaneously comforting and slightly alarming, a warmth that seems to know exactly where your tension lives and dissolves it without asking permission.
The come-up is deceptively smooth. The opioid-like body high intensifies alongside the dissociation, and the combination is extraordinarily pleasant — a sense of floating in warm darkness, untethered from gravity and worry alike. But underneath the softness there is a current of energy, a subtle stimulation that begins to make itself known as the peak approaches. Your thoughts do not simply slow — they reorganize, snapping into configurations that feel revelatory. You begin to perceive connections between ideas that normally occupy separate continents of your mind, and each connection arrives with a flush of certainty that borders on the manic. This is the compound's hidden edge: beneath the velvet surface, there is a blade.
At the peak, the warmth and the mania coexist in an uneasy marriage. You feel simultaneously sedated and driven, wrapped in cotton wool yet somehow convinced that you are thinking more clearly than you ever have. The body is profoundly numb — pain is not merely dulled but deleted, as though the nervous system has simply stopped filing those reports. Music is transcendent, each sound arriving with an emotional charge that seems almost unbearable in its intensity. Closed-eye space opens into vast, warm architectures: cathedrals of light, endless corridors lined with something that might be memory or might be invention.
The descent can be treacherous. The warmth fades before the stimulation does, and what remains is a driven, restless energy that no longer has the cushion of euphoria to soften it. Some find this phase uncomfortable — a raw, exposed wakefulness that resists sleep and invites compulsive redosing. The afterglow, when the compound finally releases its grip, is surprisingly gentle: a quiet tenderness, a sense of having been somewhere profound, and a faint residual warmth that lingers like the scent of woodsmoke in clothing.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(19)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Changes in felt gravity— A distortion of one's proprioceptive sense of gravity in which the perceived direction of gravitatio...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Orgasm suppression— Orgasm suppression (anorgasmia) is the difficulty or complete inability to achieve orgasm despite ad...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Restless legs— Restless legs is an uncomfortable neurological effect characterized by an irresistible compulsion to...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Spatial disorientation— Spatial disorientation is the inability to accurately perceive one's position or orientation within ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Tactile(2)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
- Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...
Cognitive & Perceptual Effects
Visual(9)
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
- Visual disconnection— A dissociative visual effect involving a progressive detachment from visual perception, ranging from...
Cognitive(23)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delirium— Delirium is a serious and potentially dangerous state of acute mental confusion involving disorienta...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Derealization— A perceptual disturbance in which the external world feels profoundly unreal, dreamlike, or artifici...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Thought disorganization— Thought disorganization is a cognitive impairment in which the normal capacity for structured, seque...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(2)
- Olfactory hallucination— Olfactory hallucinations (phantosmia) involve the perception of convincing phantom smells — pleasant...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(1)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
Pharmacology
NMDA Receptor Antagonism
3-HO-PCP acts as a potent non-competitive NMDA receptor antagonist through the trapping block mechanism: it enters the ion channel when open and becomes trapped, preventing ion flow. This mechanism produces the classical dissociative syndrome — analgesia, perceptual distortion, amnesia at high doses, and at sufficient doses, complete dissociative anesthesia.
Mu-Opioid Receptor Agonism
The 3-hydroxy group confers appreciable affinity for the mu-opioid receptor (MOR). Animal studies have confirmed this activity. MOR agonism adds:
- Profound analgesia beyond what NMDA antagonism alone produces
- Opioid-characteristic euphoria — "warmth," physical comfort, sedation
- Respiratory depression — the primary acute toxicity mechanism for opioids
- Physical dependence liability with repeated use
- Risk of opioid withdrawal precipitation in formerly dependent individuals
Community reports describing 3-HO-PCP's "opiate-like warmth" and notably higher euphoria than other dissociatives are consistent with this pharmacology.
Sigma Receptor Activity
Like PCP, 3-HO-PCP likely has sigma receptor activity, which contributes to additional perceptual distortions and may modulate the overall experience character.
Dopamine Reuptake Inhibition
As a PCP analog, 3-HO-PCP likely retains some dopamine reuptake inhibitory activity, adding a stimulant component and elevating abuse potential.
Combined Risk Mechanism
The critical pharmacological danger of 3-HO-PCP is the additive CNS depression from simultaneous NMDA antagonism and MOR agonism. Neither mechanism alone at a given dose may cause respiratory compromise, but together they substantially narrow the therapeutic-to-toxic margin. This is amplified dramatically by any additional CNS depressant.
Detection Methods
Standard Drug Panel Inclusion
3-HO-PCP may trigger a positive result on standard PCP immunoassay screens, though cross-reactivity is variable. The hydroxyl group at the 3-position alters the compound's interaction with immunoassay antibodies, and detection rates vary across platforms. Some assays detect 3-HO-PCP reliably, while others produce false-negative results. Notably, 3-HO-PCP is also a metabolite of 3-MeO-PCP, which means its presence in biological specimens may indicate use of either compound.
Urine Detection
3-HO-PCP is detectable in urine for approximately 3 to 7 days after a single dose. The hydroxyl group increases the compound's water solubility compared to PCP, potentially leading to slightly faster renal excretion. However, the arylcyclohexylamine core structure still promotes tissue accumulation. The primary metabolic pathway involves glucuronidation of the hydroxyl group. LC-MS/MS methods specifically targeting 3-HO-PCP and its glucuronide conjugate are required for definitive detection.
Blood and Serum Detection
Blood detection windows are 1 to 3 days. Active blood concentrations are in the nanogram-per-milliliter range. The mu-opioid receptor activity of 3-HO-PCP distinguishes it pharmacologically from other PCP analogues and contributes to its unique toxicity profile, making accurate identification in clinical toxicology important.
Hair Follicle Detection
Hair analysis for 3-HO-PCP is feasible using LC-MS/MS methods. Detection windows extend to approximately 90 days.
Confirmatory Methods
LC-MS/MS is the preferred confirmatory method. The presence of 3-HO-PCP should prompt consideration of whether 3-MeO-PCP was the parent compound consumed, and the analytical panel should include both compounds to differentiate direct 3-HO-PCP use from 3-MeO-PCP metabolism.
Reagent Testing
The Marquis reagent produces no reaction or faint yellow. The Mandelin reagent may produce a dark brown to black color. Reagent testing cannot distinguish 3-HO-PCP from other hydroxylated PCP analogues.
Interactions
| Substance | Status | Note |
|---|---|---|
| Acetylfentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Buprenorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Codeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dextropropoxyphene | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dihydrocodeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Ethylmorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Fentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Heroin | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydrocodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydromorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Kratom | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Methadone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Morphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| O-Desmethyltramadol | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxycodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxymorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Pethidine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 1,4-Butanediol | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-Fluorodeschloroketamine | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 2M2B | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1B-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-AL-LAD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-MiPLA | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
Early Pharmacological Research
3-HO-PCP was synthesized and characterized during the intensive research era of PCP analogs in the 1970s and 1980s. Researchers exploring the structure-activity relationship of phencyclidine discovered that 3-hydroxy substitution dramatically altered the receptor pharmacology — specifically conferring opioid receptor affinity. This finding was significant for understanding the pharmacology of both dissociatives and opioids, as it demonstrated that a single structural change could create a hybrid pharmacology.
Research into Endogenous Compounds
The discovery that 3-HO-PCP has opioid activity contributed to research into endogenous dissociative-like compounds and the metabolism of ketamine into norketamine and further metabolites. This research lineage has scientific value beyond the recreational context.
Research Chemical Market
3-HO-PCP entered the research chemical market in the 2010s alongside other PCP and ketamine analogs. Community discussions indicate a dedicated user base, though smaller than for more tractable dissociatives like DCK or 2-FDCK. Its dual pharmacology generates significant interest precisely because it offers an experience distinct from pure dissociatives, but the risk profile has limited broader adoption. Multiple community warnings threads (including one about a "50mg 3-HO-PCP story") have served important harm reduction functions.
Harm Reduction
Naloxone Is Essential
Anyone using 3-HO-PCP should have naloxone (Narcan) immediately available. This applies even to experienced dissociative users, as opioid-type respiratory depression can occur at doses that seem moderate based on prior ketamine or PCP experience. Ensure companions know how to administer naloxone and when to call emergency services.
Never Use Alone
The risk of respiratory depression makes solo use of 3-HO-PCP genuinely life-threatening. A sober companion who understands both opioid overdose and dissociative presentations is non-negotiable.
Avoid Absolutely if Opioid-Dependent or in Recovery
3-HO-PCP can trigger opioid withdrawal in individuals on methadone, buprenorphine (Suboxone), or naltrexone. It can also reactivate opioid cravings and is likely to contribute to relapse in those with opioid use disorder. For this population, 3-HO-PCP should be considered contraindicated.
Zero Combinations with CNS Depressants
Alcohol, opioids, benzodiazepines, GHB, or muscle relaxants combined with 3-HO-PCP are potentially fatal combinations. The respiratory depression from these combinations is additive.
Extreme Dose Conservatism
The combination of NMDA antagonism and opioid activity means the subjective "ceiling" of a given dose may not warn you before reaching a respiratory-compromising dose. Start with 2–5 mg and wait 2+ hours for full effects.
Recovery Position
If a user becomes unconscious or very sedated, place them in the recovery position (on their side) immediately to prevent aspiration. Call emergency services for any signs of respiratory compromise. Administer naloxone.
Toxicity & Safety
Respiratory Depression — Highest Priority Risk
3-HO-PCP's opioid activity creates clinically significant respiratory depression risk. Unlike ketamine, where respiratory failure requires extraordinarily high doses, 3-HO-PCP can produce respiratory compromise at doses that also produce intense dissociation. This is the primary cause of concern. Community discussions have repeatedly raised this risk, including threads exploring whether it would retrigger opioid withdrawal in formerly dependent individuals.
Opioid Overdose Risk
3-HO-PCP can produce opioid-type overdose presentations:
- Unconsciousness combined with reduced respiratory rate
- Cyanosis (blue lips/fingernails) in severe cases
- Pinpoint pupils (from opioid component)
Naloxone (Narcan) can partially reverse the opioid component but will not reverse the NMDA antagonism, meaning recovery from 3-HO-PCP overdose with naloxone may be incomplete.
Opioid Withdrawal Risk
Community discussions explicitly raise the concern that 3-HO-PCP can trigger opioid withdrawal in individuals with prior opioid use disorder or who are on medications like methadone or buprenorphine (Suboxone). This represents a meaningful clinical risk for the substantial proportion of dissociative users who have prior opioid histories.
Abuse and Dependence
The opioid-dissociative combination creates elevated psychological and physical dependence risk. Community accounts describe compulsive use patterns. Physical opioid dependence can develop with regular use, leading to withdrawal on cessation.
High-Dose Behavioral Toxicity
At doses like the 50 mg account in community records, extreme behavioral and psychological toxicity is documented — agitation, delirium, loss of self-control. This is consistent with high-dose PCP analog toxicity.
Addiction Potential
moderately addictive with a high potential for adverse side effects such as psychosis
Overdose Information
Overdose on 3-HO-PCP can range from unpleasant to life-threatening depending on the dose, route, and whether other substances are involved.
Signs of overdose: Severe nystagmus, complete unresponsiveness, vomiting (aspiration risk while unconscious), severely depressed breathing, seizures, extremely elevated heart rate or blood pressure.
Critical dangers:
- Respiratory depression: Particularly when combined with other depressants
- Aspiration: Loss of protective reflexes combined with nausea creates choking risk
- Hyperthermia or hypothermia: Impaired thermoregulation at high doses
Emergency response: Place the person in the recovery position. Monitor breathing. Call emergency services if breathing is slow, shallow, or irregular; if the person is unresponsive to stimulation; or if seizures occur. Be honest with medical personnel about what was consumed — they are there to help, not to judge.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Tolerance
| Full | with prolonged and repeated use |
| Half | 4 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Czech Republic:** 3-HO-PCP is a Schedule I (List 4) substance. It may be used for research and restricted therapeutic purposes. (§ 1, d), 1. of Nařízení vlády č. 463/2013 Sb.)
Germany:** 3-HO-PCP is not a controlled substance under the BtMG. It is legal, as long as it is not sold for human consumption, according to §2 AMG.
Switzerland:** 3-HO-PCP is a controlled substance specifically named under Verzeichnis E.
Turkey:** 3-HO-PCP is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom** - 3-HO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with a hydroxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.
Responsible use
Research chemical
PCP
3-HO-PCP (Wikipedia)
3-HO-PCP (Isomer Design)
Interview with a Ketamine Chemist (VICE)
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
Kalir, A., Elkavets, R., Maayani, S., Rehavi, M., Sokolovsky, M., Pri-Bar, I., & Buchman, O. (1978). Structure-activity relationship of some phencyclidine derivatives: in vivo studies in mice. European Journal of Medicinal Chemistry, 13(1), 17-24. https://doi.org/10.1002%2Fchin.197825192
Experience Reports (1)
Tips (9)
Start at 3-5mg for a first experience with 3-HO-PCP. This substance has a very steep dose-response curve — the difference between a pleasant experience and a medical emergency can be just a few milligrams. A 50mg dose caused heart rate of 150bpm and sharp chest pains in one report.
If insufflating 3-HO-PCP, start with a small bump and wait 15-20 minutes to assess effects before taking more. Onset via insufflation is faster than oral, but full effects still take time to manifest.
Compulsive redosing is a serious risk with 3-HO-PCP. Delusions of sobriety are common. Pre-measure your dose, lock the rest away, and set a firm rule to never redose. Many adverse reports involve people taking more because they 'did not feel it yet.'
3-HO-PCP has opioid receptor activity unlike most dissociatives. If you are on Suboxone or have opioid dependence, this substance may trigger or worsen withdrawal symptoms. Do not assume dissociatives are safe with opioid medications.
3-HO-PCP can produce significant mania and delusions of grandeur, especially at higher doses or with repeated use. Have a sober sitter who can intervene if your behavior becomes erratic. Do not use multiple days in a row.
3-HO-PCP is described as having a euphoric warmth that other dissociatives lack, likely due to its opioid activity. It combines well with psychedelic tryptamines for a grounded but immersive experience, though this combination should be approached with extreme caution.
Community Discussions (9)
See Also
References (3)
- Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- 3-HO-PCP - TripSit Factsheet
TripSit factsheet for 3-HO-PCP
tripsit - 3-HO-PCP - Wikipedia
Wikipedia article on 3-HO-PCP
wikipedia